HCV core protein augments cyclosporine immunosuppression

Area of Science:

• Immunology
• Hepatology
• Virology

Background:

• Hepatitis C virus (HCV) infection is common after liver transplantation.
• Soluble HCV proteins are suspected to modulate the immune system.
• Understanding HCV core protein's immunomodulatory effects is crucial for post-transplant management.

Purpose of the Study:

• To investigate the impact of soluble Hepatitis C virus (HCV) core protein on human T-cell proliferation and activation.
• To assess the interaction between HCV core protein and cyclosporine, an immunosuppressant drug.

Main Methods:

• Human T-cells were activated and treated with varying concentrations of HCV core protein.
• T-cell proliferation was measured using tritiated thymidine uptake and direct cell counting.
• Expression of T-cell activation markers (CD2+CD25+ and CD2+DR+) was analyzed.
• The interaction between HCV core protein and cyclosporine was evaluated using isobologram analysis.

Main Results:

• HCV core protein significantly inhibited T-cell proliferation in a dose-dependent manner (up to 92% reduction).
• Core protein treatment reduced the expression of T-cell activation markers CD2+CD25+ and CD2+DR+.
• Combining HCV core protein with cyclosporine resulted in an additive effect on T-cell proliferation suppression.

Conclusions:

• Soluble HCV core protein exhibits dose-dependent immunosuppressive properties on human T-cells.
• HCV core protein may potentiate the immunosuppressive effects of cyclosporine.
• These findings have implications for managing immune responses in liver transplant recipients with Hepatitis C.